Amit Mukesh Momaya

Amit Mukesh Momaya

Auto-generated profile, based on publicly available information

Amit Mukesh Momaya

Department of Orthopaedics University of Alabama at Birmingham Birmingham Alabama U.S.A.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2015 in Sports Medicine
Verified
Journal Article
Closed access
PDF file
AMAmit Momaya
Amit Momaya
MFMarc Fawal
Marc Fawal
REReed Estes
Reed Estes

30 September 2016 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
BSBruce A. Stewart
Bruce A. Stewart
AMAmit M. Momaya
Amit M. Momaya
MSMarc D. Silverstein
Marc D. Silverstein
DLDavid Lintner
David Lintner
Background: Competitive athletes value the ability to return to competitive play after the treatment of anterior cruciate ligament (ACL) injuries. ACL reconstruction has high success rates for return to play, but some studies indicate that patients may do well with nonoperative physical therapy treatment. Purpose: To evaluate the cost-effectiveness of the treatment of acute ACL tears with either initial surgical reconstruction or physical therapy in competitive athletes. Study Design: Economic and decision analysis; Level of evidence, 2. Methods: The incremental cost, incremental effectiveness, and incremental cost-effectiveness ratio (ICER) of ACL reconstruction compared with physical therapy were calculated from a cost-effectiveness analysis of ACL reconstruction compared with physical therapy for the initial management of acute ACL injuries in competitive athletes. The ACL reconstruction strategy and the physical therapy strategy were represented as Markov models. Costs and quality-adjusted life-years (QALYs) were evaluated over a 6-year time horizon and were analyzed from a societal perspective. Quality of life and probabilities of clinical outcomes were obtained from the peer-reviewed literature, and costs were compiled from a large academic hospital in the United States. One-way, 2-way, and probabilistic sensitivity analyses were used to assess the effect of uncertainty in variables on the ICER of ACL reconstruction. Results: The ICER of ACL reconstruction compared with physical therapy was $22,702 per QALY gained. The ICER was most sensitive to the quality of life of returning to play or not returning to play, costs, and duration of follow-up but relatively insensitive to the rates and costs of complications, probabilities of return to play for both operative and nonoperative treatments, and discount rate. Conclusion: ACL reconstruction is a cost-effective strategy for competitive athletes with an ACL injury.

10 December 2018 in Arthroscopy
Verified
Journal Article
Closed access
AMAndrew S. Moon
Andrew S. Moon
HPHarshadkumar A. Patel
Harshadkumar A. Patel
MIMatthew P. Ithurburn
Matthew P. Ithurburn
EBEugene W. Brabston
Eugene W. Brabston
BPBrent A. Ponce
Brent A. Ponce
AMAmit M. Momaya
Amit M. Momaya

1 February 2021 in Orthopaedics & Traumatology: Surgery & Research
Verified
Journal Article
Closed access
ADAlex R. Dombrowsky
Alex R. Dombrowsky
GKGraham Kirchner
Graham Kirchner
JIJonathan Isbell
Jonathan Isbell
EBEugene W. Brabston
Eugene W. Brabston
BPBrent A. Ponce
Brent A. Ponce
AMAmit M. Momaya
Amit M. Momaya

30 October 2019 in Sports Health: A Multidisciplinary Approach
Verified
Journal Article
Closed access
PDF file
AMAmit Mukesh Momaya
Amit Mukesh Momaya
AMAndrew Sullivan McGee
Andrew Sullivan McGee
ADAlexander R. Dombrowsky
Alexander R. Dombrowsky
AWAlan Joshua Wild
Alan Joshua Wild
NFNaqeeb M. Faroqui
Naqeeb M. Faroqui
BPBrent Andrew Ponce
Brent Andrew Ponce
Mixed results exist regarding the benefit of orthobiologic injections. The purpose of this study was to assess the variability in costs for platelet-rich plasma (PRP) and stem cell (SC) injections and evaluate for variables that influence pricing. There will be significant variability in the cost of PRP and SC injections throughout the United States. Descriptive epidemiology study. Level 3. Calls were made to 1345 orthopaedic sports medicine practices across the United States inquiring into the availability of PRP or SC knee injections and associated costs. In addition to pricing, the practice type, number of providers, and population and income demographics were recorded. Univariate statistical analyses were used to identify differences in availability and cost between variables. Of the contacted offices that provided information on both PRP and SC availability (n = 1325), 268 (20.2%) offered both treatments, 550 (41.5%) offered only PRP injections, 20 (1.5%) offered only SC injections, and 487 (36.8%) did not offer either treatment. The mean ± SD cost of a PRP injection was $707 ± $388 (range, $175-$4973), and the mean cost of an SC injection was $2728 ± $1584 (range, $300-$12,000). Practices offering PRP and SC injections tended to be larger (PRP, 12.0 physicians per practice vs. 8.1 [P < 0.001]; SC, 13.6 vs 9.7 [P < 0.001]). Practices that offered PRP injections were located in areas with higher median household income (P = 0.047). Variables associated with higher cost of PRP injections included city population (P < 0.001) and median income of residents (P < 0.001). While the majority of sports medicine practices across the United States offer some type of orthobiologic injection, there exists significant variability in the cost of these injections. This study demonstrates the significant variability in costs of orthobiologic injections throughout the country, which will allow sports medicine physicians to appreciate the value of these injections when counseling patients on available treatment options.

11 April 2023 in JSES International
Verified
Journal Article
Open access
SSSamuel Schick
Samuel Schick
JEJoseph Elphingstone
Joseph Elphingstone
SMSudarsan Murali
Sudarsan Murali
KCKaren Carter
Karen Carter
WDWilliam Davis
William Davis
EBeugene brabston
eugene brabston
Periprosthetic joint infections (PJIs) are a major cause of morbidity after shoulder arthroplasty. Prior national database studies have estimated the trends of shoulder PJI up to 2012.21 Since 2012, the landscape of shoulder arthroplasty has changed drastically with the expanding popularity of reverse total shoulder arthroplasty. The dramatic growth in primary shoulder arthroplasties is likely paralleled with an increase of PJI case volume. The purpose of this study is to quantify the rise in shoulder PJIs and the economic stress they currently place on the American healthcare system as well as the toll they will incur over the coming decade. The Nationwide Inpatient Sample database was queried for primary and revision anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty, and hemiarthroplasty from 2011-2018. Multivariate regression was used to predict cases and charges through the year 2030 adjusted to 2021 purchasing power parity. From 2011 to 2018, PJI was found to be 1.1% shoulder arthroplasties, from 0.8% (2011) to 1.4% (2018). Anatomic total shoulder arthroplasty experienced the greatest proportion of infections at 2.0%, followed by hemiarthroplasty at 1.0% and reverse total shoulder arthroplasty at 0.3%. Total hospital charges grew 324%, from $44.8 million (2011) to $190.3 million (2018). Our regression model projects 176% growth in cases and 141% growth in annual charges by 2030. This study demonstrates the large economic burden that shoulder PJIs pose on the American healthcare system, which is predicted to reach nearly $500 million in charges annually by 2030. Understanding trends in procedure volume and hospital charges will be critical in evaluating strategies to reduce shoulder PJIs.